Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
63 Results for "
Wee1
" in MedChemExpress (MCE) Product Catalog:
Products (63)
63 Results for "Wee1" in MCE Product Catalog:
Cat. No.: HY-161871
CAS No.: 2493422-74-3
WEE1-IN-8 (Compound 55) is a selective WEE1 inhibitor, with an IC50 of 0.98 nM. WEE1-IN-8 (Compound 55) can be used for the research of Pancreatic cancer, Ovarian cancer, Colorectal cancer, Uterine serous carcinoma, etc [1].
Cat. No.: HY-174448
CAS No.: 3069940-37-7
WEE1-IN-12 (Compound 87) is a Wee1 kinase inhibitor with an IC50 of 2.0 nM. WEE1-IN-12 can inhibit the proliferation of HT29 cells (IC50: 1.07 μM), and when used in combination with Gemcitabine (HY-17026), the effect is better (IC50: 0.34 μM). WEE1-IN-12 can be used in the research of tumors such as colon cancer [1].
Cat. No.: HY-10993R
CAS No.: 955365-80-7
Synonyms: AZD1775 (Standard); MK-1775 (Standard)
Target:
Research Areas:
Adavosertib (Standard) is the analytical standard of Adavosertib. This product is intended for research and analytical applications. Adavosertib (AZD-1775; MK-1775) is a potent Wee1 inhibitor with an IC50 of 5.2 nM.
Cat. No.: HY-172807
CAS No.: 2133007-20-0
Target:
Research Areas:
p38α-IN-9 (Compound 2015) is a p38α inhibitor and blocks p38α’s enzymatic activity with an IC50 lower than 20 nM. p38α-IN-9 inhibits MK2 T334 phosphorylation. p38α-IN-9 activates Cdc25b and Cdc25c and simultaneously inactivates Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy and DNA damage. p38α-IN-9 Inhibits colorectal cancer (CRC) metastasis [1].
Cat. No.: HY-RS15805
Target:
Research Areas:
WEE1 Human Pre-designed siRNA Set A contains three designed siRNAs for WEE1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS15806
Target:
Research Areas:
Wee1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Wee1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS15807
Target:
Research Areas:
Wee1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Wee1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-179272
CAS No.: 3037071-29-4
Wee1/HDAC-IN-1 is a dual Wee1/HDAC inhibitor with an IC50 of 1.2 nM for Wee1 and IC50 values of 196 nM for HDAC1, 156 nM for HDAC3, and 55 nM for HDAC6. Wee1/HDAC-IN-1 exhibits strong antiproliferative activity against MV4-11 cells with an IC50 of 0.076 μM. Wee1/HDAC-IN-1 selectively binds to Wee1 and HDACs. Wee1/HDAC-IN-1 interferes with DNA damage repair pathways and induces apoptosis in MV4-11 cells. Wee1/HDAC-IN-1 Wee1/HDAC-IN-1 can be used for the research of acute myeloid leukemia (AML) [1].
Cat. No.: HY-169946A
CAS No.: 3047759-59-8
WEE1/PKMYT1-IN-2 is the axial chiral P configuration of WEE1/PKMYT1-IN-1 (HY-169946). WEE1/PKMYT1-IN-1 is a potent and orally active WEE1 and PKMYT1 inhibitor. WEE1/PKMYT1-IN-1 shows antiproliferation activity [1].
Cat. No.: HY-169946B
CAS No.: 3047759-60-1
WEE1/PKMYT1-IN-3 is the axial chiral M configuration of WEE1/PKMYT1-IN-1 (HY-169946). WEE1/PKMYT1-IN-1 is a potent and orally active WEE1 and PKMYT1 inhibitor. WEE1/PKMYT1-IN-1 shows antiproliferation activity [1].
Cat. No.: HY-143342
CAS No.: 2858812-89-0
LEB-03-144 is a WEE1 DUBTAC (deubiquitinase-targeting chimera) linking AZD1775 (Adavosertib) to the OTUB1 recruiter EN523 through a C3 alkyl linker. LEB-03-144 shows significant WEE1 stabilization in HEP3B hepatoma cancer cells [1].
Cat. No.: HY-178150
CAS No.: 2803921-87-9
WEE1-IN-14 (Compound 14) is a selective WEE1 inhibitor (IC50: 0.5 nM in L-RB-FEP calculations, 1.0 nM in ADP-Glo kinase assay). Inhibition of Wee1 in cancer cells disrupts the G2-M checkpoint, removes the regulatory controls on the cell cycle, and leads to early onset of mitotic failure followed by apoptosis of tumor cells. Therefore, WEE1-IN-14 is a useful tool for studying cancer biology [1].
Cat. No.: HY-168180
CAS No.: 2975172-98-4
WEE1-IN-11 (Compound 13) is a potent CDK2 inhibitor with an IC50 of 2.0 nM. WEE1-IN-11 inhibits NCI–H446, A427, OVCAR3, C33A,and WiDr cells with IC50s of 93.9, 34.5, 86.7, 23.1, and 85 nM, respectively [1].
Cat. No.: HY-133702
CAS No.: 643087-19-8
Target:
Research Areas:
Aniline-piperazine-C3-NH-Boc (Compound Int-3) is a PROTAC linker, and can be used for synthesis of Pomalidomide-C3-adavosertib (HY-133618) and AZD1775 (HY-10993) (a Wee1 inhibitor) [1].
Cat. No.: HY-172759
CAS No.: 3055031-36-9
PKMYT1-IN-9 is a highly selective and orally active PKMYT1 inhibitor (IC50: 4.4 nM). PKMYT1-IN-9 shows more selective for PKMYT1 than WEE1 (IC50: 32.4 μM). PKMYT1-IN-9 exhibits antitumor activity [1].
Cat. No.: HY-176363
CAS No.: 2113725-19-0
Research Areas:
Adavosertib-C3-NH-Boc is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for Wee1 (HY-10993) and a PROTAC linker (HY-W011561), which recruits E3 ligases. Adavosertib-C3-NH-Boc can be used for synthesis of PROTAC Pomalidomide-C3-adavosertib (HY-133618) [1].
Cat. No.: HY-133703A
CAS No.: 2858813-30-4
i-AZD1775 TFA is a Target Protein Ligand-Linker Conjugate that contains a target protein ligand and a PROTAC linker, and can recruit E3 ligases. i-AZD1775 TFA can be used for the synthesis of Pomalidomide-C3-adavosertib (HY-133618). i-AZD1775 TFA is an immobilizable analogue of AZD1775. i-AZD1775 TFA retains the ability to inhibit WEE1 in vitro. i-AZD1775 TFA can be studied in anticancer research [1].
Cat. No.: HY-175261
Target:
Research Areas:
DHI1 is an anti-leukemia agent with high selectivity for Jurkat (IC50 = 21.83 μM) and HL-60 (IC50 = 19.14 μM) leukemia cells and has low toxicity to non-cancerous cells. DHI1 can induce G2/M phase cell arrest in Jurkat and HL-60 leukemia cells, as well as S phase arrest in HL-60 cells, and has significant effects on cell cycle signaling molecules Wee1, cyclin B1, cdc2 on Tyr15, and Chk1. DHI1 inhibits the migration and invasion of Jurkat and HL-60 cells by disrupting cytoskeletal actin filaments. DHI1 can be used to study hematological malignancies [1].
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
